Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in PML at the site of arsenic binding appears to be the main mechanism of resistance.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: